Stockholm-Uppsala is Scandinavia’s leading life-science cluster and a major player in a European context. The region’s healthcare infrastructure is complemented by the dynamic gathering of world-leading researchers, universities, companies big and small and key regulatory authorities that all call the region their home.
If you’re looking for commercial projects to develop for the market or international cross-disciplinary partnership for your research, investing in life science companies in the Stockholm region brings good return on investment.
Easy access to innovative companies
A researcher employed at a Swedish university owns the rights to all intellectual property generated by their research. This teacher’s exemption, and the close links between research and industry in the region make it easy to transform life-science ideas into healthcare products with commercial potential.
Stockholm-Uppsala is one of the strongest regions in the world when it comes to the number of life science start-ups. More than 15 new life science companies were formed each year during the last decade. This is on par with life science regions such as Boston.
Much of the research conducted in the region is channeled into the life science industry, and big pharma companies. Swedish biotech companies have established a number of international partnerships and there are a considerable amount of drug candidates that are in the pipeline for development.
World class research and unique infrastructure
The dynamic Stockholm-Uppsala region offers world-class scientific excellence through academic institutions including Karolinska Institute, Uppsala University, Stockholm University and Royal Institute of Technology-KTH.
Of the 16 Nobel Prizes Sweden has produced, six of the prizes have been awarded to research conducted in the Stockholm-Uppsala region in Physiology or Medicine.
Stockholm-Uppsala offers an excellent research infrastructure and unique resources such as biobanks that allow epidemiological research and genetic studies.
A strong life science cluster located next to one of the world’s strongest ICT clusters drives forward research and innovation in the fields of medtech and IT medicine.
Join in the development of tomorrow’s healthcare
The science of medicine is developing rapidly, and there are continuous advances being made in new work methods and processes. Government is committed to investing in the development of tomorrow’s healthcare in order to meet new demands on modern healthcare systems.
Construction of the New Karolinska Solna University Hospital is underway. It is the largest project ever undertaken by the Stockholm County Council as well as being one of the largest and most innovative healthcare projects worldwide. When completed in 2015, the New Karolinska Solna University Hospital will be a modern site for specialized healthcare, research and education.
Unique advantages in brief
Leadership: World leading research in stem cells, HPA (human protein atlas), mobile medtech, proteomics, nanotechnology, life gene, biobanks, sci life lab
Experience: Unique expertise in clinical trials and patient registers, protein research cardiovascular diseases, CNS, cancer bio production
Innovation: Leading the innovation scoreboard, high number of innovative companies, numerous products from the combined network of academia and enterprise,
Karolinska Development has recently documented its 1000th innovation
Investment Opportunities
The Stockholm-Uppsala region offers investment opportunities including in-licensing, collaboration, and direct investment in:
Medtech industry
- Cardiology
- Imaging
- E-health diagnostics
- Orthopedics
Biotech and Pharma industries
- Metabolic
- Cardiology
- Cancer
- Central Nervous System